Podoplanin (PDPN) is expressed on many tumors and is involved in tumor metastasis. The objective of the present study was to develop an ELISA for determining soluble PDPN (sPDPN) levels as a potential novel tumor marker in plasma of patients with cancers for detection of tumor occurrence and metastasis. Mouse monoclonal antibodies (mAb) against human PDPN were developed and characterized. Two anti-PDPN mAb, SZ-163 and SZ-168, were used in a sandwich ELISA to detect plasma sPDPN in patients with cancers and in normal individuals. The levels of sPDPN were detected in patients with adenocarcinoma (87 cases, 31.09 AE 5.48 ng/ ml), squamous cell carcinoma (86 cases, 6.91 AE 0.59 ng/ml), lung cancer (45 cases, 26.10 AE 7.62 ng/ml), gastric cancer (38 cases, 23.71 AE 6.90 ng/ml) and rectal cancer (27 cases, 32.98 AE 9.88 ng/ml), which were significantly higher than those in normal individuals (99 cases, 1.31 AE 0.13 ng/ml) (P < .0001). Moreover, the sPDPN levels in patients with metastatic cancers were higher (192 cases, 30.35 AE 3.63 ng/ ml) than those in non-metastatic cancer patients (92 cases, 6.28 AE 0.77 ng/ml) (P < .0001). The post-treatment sPDPN levels of cancer patients (n = 156) (4.47 AE 0.35 ng/ml) were significantly lower compared with those seen pre-treatment (n = 128) (43.74 AE 4.97 ng/ml) (P < .0001). These results showed that an ELISA method was successfully established for quantitation of plasma sPDPN and plasma sPDPN levels correlate significantly with tumor occurrence and metastasis.
structural domains: a highly O-glycosylated extracellular domain, a hydrophobic transmembrane domain, and a short cytoplasmic domain.
11,12 PDPN induces platelet aggregation through direct binding of its extracellular domain to C-type lectin-like receptor 2 (CLEC-2) expressed on the platelet surface. 13 Thus, PDPN plays an important role in lymphatic vascular development and in cancer metastasis through interaction with CLEC-2. 14,15 PDPN is also expressed in cancer-associated fibroblasts (CAF) where it facilitates lung adenocarcinoma cell invasion by activating the Rho-ROCK pathway via its cytoplasmic domain. 16 In addition to the form of PDPN expressed on the cell surface, a soluble form of PDPN (sPDPN) has recently been detected and investigated. Carrasco-Ramirez et al report that cells ectopically or endogenously expressing PDPN release membrane-shed micro-vesicles (MV) and endosomal-derived exosomes (EXO) that contain PDPN mRNA and protein.
In vitro study suggested a crucial role of PDPN in EXO and MV production and/or release and for PDPN-EXO in tumorigenesis. 17 Those PDPN-EXO may account for PDPN in circulating fluids in vivo because PDPN + microparticles were identified in pleural effusions of both cancer and benign origin in humans. 18 However, given the expression of PDPN in tumors, sPDPN is a promising biomarker because of the potential ease of its measurement in serum. To this end, Sankiewicza et al used surface plasmon resonance to quantitate sPDPN in the serum and urine of bladder cancer patients and healthy volunteers and found that the PDPN levels in the patient samples were higher than that of the healthy controls. 19 To date, several anti-PDPN monoclonal antibodies with high sensitivity and specificity have been developed. Among these, NZ-1 reacts with the platelet aggregation-inducing (PLAG) domain of human PDPN, thereby inhibiting PDPN-induced platelet aggregation in vitro and suppressing cancer metastasis in vivo. 20, 21 Immunohistochemistry conducted using another PDPN antibody, D2-40, has been used to detect tumor metastasis and significantly increased the detection frequency of lymphatic invasion compared to the use of conventional HE staining in squamous cell carcinoma. 22 However, few antibodies targeting sPDPN have been generated, and both immunohistochemistry and surface plasmon resonance are relatively difficult and expensive analyses. 23 and the U87 astroglioma cell line were stored in our laboratory. The NCI-H226 lung squamous cell line was purchased from Jiangsu KeyGEN BioTECH (Nanjing, China).
| Cell culture
Chinese hamster ovary, CHO-PDPN and U87 cells were cultured in DMEM (Hyclone, Logan, Utah, America), supplemented with 10% FBS (Gibco, Carlsbad, CA, USA). NCI-H226 cells were cultured in RMPI-1640 medium (Gibco), supplemented with 10% FBS (Gibco). 
| Polypeptide synthesis and coupling

| Western blot analysis
Cells were solubilized using RIPA lysis buffer (Beyotime Biotechnology, Shanghai, China) and the lysates were separated in reduced SDS-PAGE followed by transfer to a PVDF membrane (Millipore, Darmstadt, Germany 95 AE 2.49 ng/ml) was significantly higher than that in the normal individuals (1.33 AE 0.14 ng/ml) as compared by the Mann-Whitney test analyses (P < .0001) ( Figure 2B ).
| Soluble podoplanin levels in patients with
various cancer types before and after treatment Figure 2B,C) . Moreover, the post-treatment plasma sPDPN levels of cancer patients (n = 156) (4.47 AE 0.35 ng/ml)
were significantly lower compared with those seen pre-treatment (n = 128) (43.74 AE 4.97 ng/ml) ( Figure 3 ). For each cancer type, the plasma sPDPN level of the post-treatment group was significantly lower than that of the pre-treatment group, especially in squamous cell carcinoma, adenocarcinoma and lung cancer (Figure 3) . The pre-treatment group consisted of patients that did not receive any surgery, chemotherapy or radiotherapy, while the post-treatment group consisted of patients 3-7 days after surgery or those that received at least one course of radiation/ chemotherapy. The cancer patients were divided into 2 groups according to whether their tumor was metastatic or not, and sPDPN levels in the 2 groups were analyzed using a Mann-Whitney test. The sPDPN level was 30.35 AE 3.63 ng/ml in the plasma of the metastatic group (n = 192) and 6.28 AE 0.77 ng/ml in that of the non-metastatic group (n = 92), and this difference was statistically significant (P < .0001) ( Figure 4A ).
For pre-treatment cancer patients (n = 129), the sPDPN values ranged from 0.90 to 185.40 ng/ml (63.16 AE 6.74 ng/ml) in the metastatic group (n = 84), compared with 0.64 to 39.60 ng/ml (7.43 AE 1.35 ng/ml) in the non-metastatic group (n = 45). The plasma sPDPN level in the non-metastatic group was significantly lower than that in the metastatic group of the pre-treatment patients (P < .0001) ( Figure 4B ). For specific cancer types, the plasma sPDPN level in the nonmetastatic group with adenocarcinoma pretreatment was significantly lower than that in the metastatic group (P = .0004) ( Figure 4D ). However, the difference between the non-metastatic and metastatic groups diminished after treatment (P = .3502) (Figure 4D ). The comparison of plasma sPDPN levels between the nonmetastatic and metastatic groups pre-treatment and post-treatment was more obvious in adenocarcinoma than other cancer types, for example, lung cancer (P = .1566 vs P = .9113) and rectal cancer (P = .2803 vs P = .2007) (Fig. S1 ). To detect sPDPN in the plasma and explore its biological function, we generated 2 new anti-human PDPN mAb (SZ163 and SZ168) and developed a double-antibody sandwich ELISA to quantitate plasma sPDPN, using SZ-163 as the coating antibody and HRP-SZ-168 as the detecting antibody. The ELISA results showed that the levels of sPDPN in tumor patients with adenocarcinoma, squamous cell carcinoma, and rectal, lung and gastric cancers were significantly higher than those of normal individuals (P < .0001) (Figure 2 ).
Furthermore, sPDPN levels in metastatic cancer patients were significantly higher than those of non-metastatic cancer patients (P < .0001) (Figure 4) . Therefore, our ELISA provided an easier, faster and more reliable way to detect sPDPN in plasma compared with the previously reported surface plasmon resonance method. The ELISA could be applied on a large scale at a reasonable cost to diag- anti-non-PLAG hPDPN mAb, can be used for detecting different glycan profiles of hPDPN, including the poly LacNAc structure. 35 Evidence from the PDPN CasMab suggest the diversity of PDPN glycosylation among different cancer cells.
In our study, the plasma sPDPN level in cancer patients posttreatment was significantly lower compared with pre-treatment cancer patients. The difference was more significant in cancer types with high expression of PDPN, such as squamous cell carcinoma, adenocarcinoma or lung cancer than other cancers (Figure 3 ), suggesting the specificity of sPDPN as a cancer biomarker. In addition, in squamous cell carcinoma, the plasma sPDPN from patients who underwent chemotherapy or surgery and chemotherapy were significantly lower than those of pre-treatment patients, while this was not true of patients who underwent surgery alone (Fig. S2) . These results Additional studies that include expanded numbers of cancer patients and cancer types will be required for further testing of the sPDPN-specific mAb and ELISA system. However, the results of this study strongly suggest that optimization of sPDPN as a reliable marker for detection and diagnosis of tumor occurrence and metastasis under more complicated pathological circumstances is warranted.
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